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1. Introduction 
Oral liquids are homogenous preparations containing one or 
more active ingredients dissolved or suspended in a suitable vehicle. 
They are intended to be swallowed either undiluted or after dilution. 
Suspension is a heterogenous system consisting of internal phase or 
suspended phase, which is made up of the particulate matter, dispersed 
uniformly with mechanical agitation throughout the external phase with 
the help of suspending agents, which is generally a liquid or semisolid. 
The particle size in the suspension ranges above 0.1µm. The dispersed 
phase may consist of discrete particles or it may be a network of 
particles, resulting from particle-particle interaction. The drugs are 
dispersed as suspensions for different reasons, but the most common one 
is poor aqueous solubility. The suspension offer greater stability to drug 
as it is not in solution form and in some cases enhanced bioavailability 
also occurs. The suspension can be easily administered to children of 
different ages by adapting the volume to swallow [1]. 
Cefixime is third generation cephalosporin antibiotic of the 
amino thiazol class. Cefixime exerts its bacterial effect by inhibiting 
protein synthesis and so inhibiting cell wall biosynthesis of bacteria. It’s 
having shorter half life (3-4 hr), which enables daily single dose (400 mg) 
or twice a day (2*200 mg). Cefixime is used to treat many of bacterial 
infection. It is mainly used to treat peptic- ulcer, typhoid- fever, 
pneumonia, urinary tract infection, etc. In children less than 6 months, 
cefixime has not established its safety and efficacy. Cefixime is poorly 
water soluble drug, when it formulated as pellets, showed enhancement 
in bioavailability of drug [2]. 
Multiparticulate dosage forms such like beads, microspheres, 
microcapsules, pellets now to be most popular rather than non 
disintegrating single unit dosage forms. They having more surface area 
by which disintegrate more uniformly in GIT, resulting in more 
absorption and more bioavailability and reduce local irritancy and also 
avoid the unwanted intestinal retention of polymeric material. Also, the 
multiparticulate dosage forms are being formulated as liquid suspensions 
that are the ideal dosage form for pediatrics and geriatric patients due to 
their flexibility in measurement of dose, ease of swallowing, pleasant 
taste and attractive coloring and flavoring agent [3]. 
The concept of pellets can be utilized to provide a long lasting 
release of drug for local and systemic action. Extrusion and 
Spheronization generates multiunit matrix based particulate system that 
produce multiparticulate with spherical shape, good flow properties, low 
friability and uniform packing characteristics. Pellets can accommodate 
high drug loads, and modified drug release [4]. Whereas suspension 
includes taste masking of drug, higher patient compliance, reduce side 
effects and increase in rate of absorption of drug. 
Abstract 
The aim of present research work was undertaken with the objective of design and 
development of Fast disintegrating tablet to form sustained release suspension of Cefixime by 
Extrusion and Spheronization technique using sodium alginate, Eudragit RS100 and Eudragit 
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batches showed flow property in acceptable range, and % friability in <1%. All the batches 
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Release rate constant (k). Optimized formulation (F9) showed 98.76% drug release at the end of 
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Theoretical release profile of Cefixime. 6% of Crosscarmelose sodium disintegrate tablet in <50 
sec. Batch  F7- F9 showed disintegration in 42-43 sec. optimum concentration of xanthan gum was 
found to be 0.5% as suspending agent. F9 batch showed less disintegration time and number of 
strokes required very less of 7.0. Optimize formulation was stable after 18 days. Cefixime 
reference suspension showed good property and dissolution profile compared to marketed 
product (ZIFI100). 
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2. Materials and Methods 
2.1 Materials 
Cefixime was obtained as a gift sample from National 
pharmaceuticals, India. Eudragit RS100 and Eudragit RL100 were 
obtained as a gift sample from Evonic Degussa, India. Sodium alginate 
and Xanthan gum were obtained as gift sample from Finar chemicals, 
Mumbai, India. Crosscarmelose sodium was obtained as a gift sample 
from Lesar Chemicals Ltd. Mumbai, India. Microcrystalline cellulose was 
obtained as a gift sample from Chemodyes Corporation. All others 
reagents and chemicals used were of analytical reagent grade. 
2.2 Methods 
2.2.1 Preparation of Cefixime Pellets 
Pellets were prepared by Extrusion and Spheronization 
technique. Cefixime as active ingredient, polymers (Sodium alginate, 
Eudragit RS100 and Eudragit RL100) and others ingredients were mixed 
in polyethylene bag for 5 min. In above mixture isopropyl alcohol (IPA) 
was added to make dump mass in mini-mixer (Table 1). Prepare dump 
mass were subjected to undergoes to extrusion then, resultant extrudate 
subjected to Spheronization to get desired pellets at specified speed 
(700rpm, 800rpm and 900rpm) for 15 minutes. Pellets were formed and 
Collected in tray. Pellets were dried in hot air oven at temperature of 50 
0C. 
Table 1: Formulation Composition of Cefixime Pellets 
Ingredient 
(%) 
Formulations code 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
Spheronization Speed (rpm) 
500 rpm 700 rpm 900 rpm 
Cefixime  20 20 20 20 20 20 20 20 20 
Eudragit RS100 10 15 20 10 15 20 10 15 20 
Sodium alginate 20 15 10 20 15 10 20 15 10 
MCC 40 40 40 40 40 40 40 40 40 
PEG400 1 1 1 1 1 1 1 1 1 
CaCO3 5 5 5 5 5 5 5 5 5 
DCP 4 4 4 4 4 4 4 4 4 
IPA q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. 
 
2.2.2 Preparation of Fast Disintegrating Tablets 
Accurately weigh all the ingredients. Mix all the excipients 
(Xanthangum, crosscarmelose sodium, sodium citrate, sodium benzoate, 
flavor, color, magnesium Stearate and talc) according to geometric ratio. 
Take 200 mg Eq. Wt. of cefixime pellets. Mix cefixime pellets with above 
materials and add sucrose up to 1500 mg of the total weight of mixture 
(Table 2). Set the die cavity by 16mm punch in tablet punching machine. 
Take all above materials in die cavity and compress the tablet and 
evaluate it. 
Table 2: Formulation Composition of Fast Disintegrating Tablets 
Ingredients 
(%) 
Formulations code 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
Cefixime Pellets 200mg eq. wt. of cefixime 
Xanthan Gum 0.1 0.3 0.5 0.1 0.3 0.5 0.1 0.3 0.5 
Crosscarmelose Sodium 2 2 2 4 4 4 6 6 6 
Sodium Citrate 1 1 1 1 1 1 1 1 1 
Sodium Benzoate 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
Cherry Flavour q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. 
Colour q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. 
Magnesium Stearate 1 1 1 1 1 1 1 1 1 
Talc  1 1 1 1 1 1 1 1 1 
Sucrose Up to 
1500 mg 
Up to 
1500 mg 
Up to 
1500 mg 
Up to 
1500 mg 
Up to 
1500 mg 
Up to 
1500 mg 
Up to 
1500 mg 
Up to 
1500 mg 
Up to 
1500 mg 
 
2.2.3 Preparation of Reconstitutable Sustained Release Suspension 
The fast disintegrating tablet was put in 30 ml of pure water 
containing glass and it disintegrates and form suspension. 
Optimization of Variable Using Full Factorial Design 
A 32 randomized full factorial design was used in the present 
study. In this design, 2 factors were evaluated; each 3 levels and 
experimental trials were performed for all 9 possible combinations. The 
polymer to copolymer ratio of sodium alginate and Eudragit RS100 (X1) 
and spheronization speed (X2) were chosen as independent variable in 32 
full factorial design (Table 3), while  Q6 (% drug release at 6 hours), t50 
(time required for 50% drug release), t90 (time required for 90% drug 
release) were taken as dependent variables. 
A 32 randomized full factorial design was used in development 
of dosage form. A statistical model incorporating interactive and 
polynomial terms was utilized to evaluate the response (Equation 1). 
 
Y=b0+b1X1+b2X2+b11X1X1+b22X2X2+b12X1X2    ……………........ (1) 
 
Where, 
Y = dependent variable 
b0 = arithmetic mean response of the 9 runs 
bi =estimated coefficients for the factor Xi 
The main effect (X1andX2) represents the average result of 
changing one factor at a time from its low to high value. The interaction 
term (X1X2) shows how the response changes when two factors are 
change simultaneously. The polynomial terms (X1X1, X2X2) are included to 
investigate nonlinearity [5,6]. 
 
Table 3: Low, Intermediate and High level values for each factor 
Selection of level for independent variable 
Coded Value X1 (Ratio of polymer to 
copolymer, ratio in %) 
X2 (Speed of 
Spheronization) 
-1 10:20 500 
0 15:15 700 
+1 20:10 900 
*X1=polymer ratio, X2=spheronization speed 
Table 4: 32 Full Factorial Designs for Pellets 
Batch Code Coded Value Uncoded Value 
X1 X2 X1 (%) X2 (%) 
1 -1 -1 10:20 500 
2 0 -1 15:15 500 
3 +1 -1 20:10 500 
4 -1 0 10:20 700 
5 0 0 15:15 700 
6 +1 0 20:10 700 
7 -1 +1 10:20 900 
8 0 +1 15:15 900 
9 +1 +1 20:10 900 
*X1= Ratio of polymer, X2= Spheronization speed 
The composition of factorial design batches (F1-F9) is shown in 
table 4. The prepared formulations were evaluated for flow property, % 
practical yield, % drug loading, particle size, friability and in vitro drug 
release study. 
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2.3 Validation of Experimental Design 
2.3.1 Check Point Batch 
 Polynomial equations were generated using Statistica 8 for 
selected responses like % yield, particle size, encapsulation efficiency, 
Q6.Q8, t90%, Exponential constant (n) and release rate constant (k).The 
generated polynominal equations were further reduced on the basis of 
significant terms obtained by applying ANOVA. The design was validated 
by preparing an extra check point formulation. The predicted values for 
response were determined on the basis of respective polynomial 
equations whereas the experimental values were determined by 
evaluating formulation for dependent variable. The predicted and 
experimental values of responses were compared for statistical 
significance using paired t –test [7]. 
2.3.2 Drug-Excipient Compatibility Studies  
Fourier-transformed infrared (FT-IR) spectroscopic studies 
were performed to check the compatibility between drug and polymer in 
formulations. The FT-IR spectra of drug alone and with formulation 
polymers were obtained by KBr (Potassium Bromide) disk method and 
compared with the standard FT-IR spectrum of the pure drug.  
2.3.3 Evaluation of Flow Properties of Pellets 
Prepared pellets were evaluated for various parameters such 
as angle of repose, loose bulk density, tapped bulk density, 
compressibility index and Hausner’s ratio [8, 9, 10].  
2.4 Evaluation of Optimized Batches of Pellets 
2.4.1 Friability  
Accurately weighed quantity of pellets (3 gm) were taken from 
final batch of pellets and placed in a Friabilator and tumbled for 100 
revolutions at 25 RPM. Twelve steel balls (Weighing 0.445 gm each) were 
used as attrition agent. Subsequently, the pellets were sieved through 
sieve no. 20 [11]. The weight loss (%) is calculated as (Equation 2): 
F (%) = (Wi –Wr /Wi)*100   ………………… (2) 
Where, Wi is initial weight of pellets before friability testing, 
and Wr is the weight of pellets retained above the sieve after friability 
testing. 
2.4.2. Drug loading (%) 
The 100 mg Pellets were crushed and  was dissolved in 10 ml 
methanol and then transferred to 100 ml of 0.1 N HC1 in volumetric flask. 
The solution was analyzed at 285 nm using double beam UV-Vis 
spectrophotometer after suitable dilution. The % drug loading was 
calculated from calibration curve [12,13]. 
2.4.3. Practical yield (%) 
The percentage of production yield (wt/wt) was calculated 
from the weight of dried pellets (w1) recovered from each of batches and 
the sum of the initial dry weight of starting materials (w2). The formula 
for calculation of percentage yield is as follows in Equation 3 [14]. 
% Practical Yield = (Practical Value / Theoretical Value)*100 
…………….. (3) 
2.4.4. Particle size and size distribution  
The size and size distribution of the pellets produced was 
determined by agitation for 10 min with a sieve shaker fitted with a 
progression of standard sieves. From the weight retained on each sieve 
particle size is determined from standard sieve aperture size as per 
Indian pharmacopeia. 
2.4.5 In-Vitro Dissolution Study 
The  in  vitro dissolution  study  of 200 mg eq. wt. of cefixime 
pellets  were  performed  as described in  Indian  Pharmacopoeia  2010  
using  USP  apparatus  II  fitted  with  paddle (50  rpm)  at 37 C̊  ±  0.5 C̊  
using  Simulated  gastric  fluid  (pH  1.2;  700  ml)  as  a dissolution 
medium for first 2 hour and followed by phosphate buffer (pH 7.2; 
900ml) by  adding  200  ml  of  0.2  mol/L  tri  sodium  phosphate  in  
dissolution  media  for remaining  hours.  At  the  1  hrs  time  intervals,  
5ml  samples  were  withdrawn,  and analysed  at  285 nm in 0.1n HCL 
and 288 nm in 7.2 pH phosphate buffer  using  a  Shimadzu  UV  1800  
double-beam  spectrophotometer (Shimadzu, Kyoto, Japan). Cumulative 
percentage drug release was calculated using an equation obtained from 
a calibration curve which is developed in the range of 4-20 µg/ml for 
0.1N HCl and pH-7.2 phosphate buffer. All dissolution experiments were 
done in triplicate, under sodium lamp[15]. 
2.5 Evaluation of Fast Disintegrating Tablets 
The prepared fast dissolving tablets were evaluated for 
hardness, thickness, weight variation, thickness, friability, content 
uniformity, disintegration time, wetting time and in vitro dissolution 
studies. Hardness of the tablets was tested using Rimek-K-DHT 100. 
Friability of the tablets was tested using Roche friabilator (Electrolab EF-
2-USP). The thickness of the tablets was tested using vernier caliper 
(Mitutoyo CD-6, Japan). Weight variation test was performed according 
to Indian Pharmacopoeia 2010. 
2.5.1 In-vitro drug release study 
In-vitro drug release study for the prepared tablets were 
performed as described in Indian Pharmacopoeia 2010 using eight-
station USP type II (Paddle) apparatus at 37°C ± 0.5°C and 50rpm speed. 
The dissolution studies were carried out in 900ml media of acid buffer of 
pH 1.2 for two hour and in phosphate buffer of pH 7.2 for remaining 
hours under sink condition. At predetermined time intervals, a 10 ml 
sample was withdrawn and replaced with fresh dissolution medium to 
maintain the volume constant. The samples withdrawn were filtered 
through a whatman filter paper and drug content in each sample was 
analyzed by double-beam UV-spectrophotometer (Shimadzu 1800, 
Kyoto, Japan) after suitable dilution at 285nm (1.2 pH of 0.1N HCl) and 
288nm (7.2 pH phosphate buffer). The amount of drug present in each 
sample was calculated with the help of appropriate calibration curve and 
compared with reference standard.  
2.6 Evaluation Parameter of Reconstitutable Suspension 
2.6.1 Organoleptic property of suspension 
It was evaluated by visual inspection, odour and colour was 
evaluated for each of batch of suspension. 
2.6.2 pH  
The pH of reconstitutable suspension was determined by using 
digital pH meter. 
2.6.3 Viscosity 
The viscosity of suspension was determined by Brookfield 
viscometer. In adepter 15 ml of suspension was taken and the adepter is 
set over the viscometer by a stand such a way that spindle is completely 
immersed in the suspension. Spindle number 3 was used. 
2.6.4 Sedimentation volume 
10 ml of each suspension was taken in 50 ml stopper 
graduated measuring cylinder. The suspension was dispersed thoroughly 
by moving upside down for three times. Later, the suspension was 
allowed to settle for three minutes and the height of sediment was noted. 
This was the original height of sediment (H0). The cylinder was kept 
undisturbed for 7 days. The height of sediment read at every 24 hr for 7 
days was considered as final height of sediment (Hu) (Equation 4). 
2.6.7 Sedimentation Volume (F) = Hu/H0   …………………………… (4) 
The ultimate height of the solid phase after settling depends on 
concentration of solid content. To obtain an acceptable suspension, F 
should be at least 0.9 for 1hour but a longer period was preferred for our 
purpose. 
2.6.8 Redispersibility  
Fixed volume of each suspension (10 ml) was kept in 
stoppered cylinder which was stored at room temperature for 7 days. 
The redispersibility was determined by studying number of strokes to 
redisperse the formed sediment at the end of 7 days of storage of the 
formulation [16-19]. 
2.6.9 Drug Release Kinetics 
The rate and mechanism of in-vitro drug release from 
prepared dosage form was analyzed by fitting dissolution data into Zero-
order (cumulative amount of drug release versus time), First-order (log 
cumulative percentage of drug remaining versus time), Higuchi 
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(cumulative percentage of release versus square root of time) Hixson-
Crowell model, and Korsmeyer-Peppas (log cumulative percentage of 
drug released versus log time) equation models [20]. 
2.7 Statistical Analysis 
 The statistical analysis of the factorial design batches was 
performed by multiple regression analysis using Microsoft Excel. 
2.8 Similarity factor (f2) 
To evaluate and comparison of dissolution profiles, the 
dissolution profiles were analyzed using similarity factor f2. The equation 
5 for calculating f2 is given below.  
Similarity factor f2 
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Where, n is numbers of dissolution time point, Wt is optional 
weight factor, Rt is reference dissolution point at time t and Tt is test 
dissolution point at time t. The f2 value between 50 and 100 suggests that 
the dissolution profiles are similar. The f2 value of 100 suggests that the 
dissolution profiles are similar. The f2 value of 100 suggests that the test 
and reference profiles are identical and as the value becomes smaller, the 
dissimilarity between releases profile increases. 
2.9 Dissimilarity factor (f1) 
The dissimilarity factor (f1) calculates the percent difference 
between the two curves at each time point and is a measurement of the 
relative error between the two curves (Equation 6). 
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Where n is the number of time points, Rt is the dissolution 
value of the theoretical dissolution profile at time t and Tt is the 
dissolution value of the formulation at time t. The values should lie 
between 0-15.For curves to be considered similar f1 values should be 
close to 0 [20,21]. 
2.10 Accelerated Stability Studies  
The accelerated stability study was done of optimize 
formulation for 18 days. To determine the change in physical properties 
and in vitro release profile on storage, optimized batch F9 were stored at 
25oC±2oC/60% RH±5% RH and 40oC±2oC/75% RH±5% RH for 18 days. 
Samples were taken and evaluated for their redispersibility, 
sedimentation volume, CPR at a suitable time intervals and also, physical 
stability (colour, odour and pH) changes for the samples were examined 
[22]. Comparison of prepared suspension with marketed Cefixime 
Suspension (Zifi100). The prepared suspension was compared with 
marketed Cefixime Suspension formulation. Viscosity, redispersity, 
sedimentation volume, and in-vitro drug release study of suspension was 
compared. 
 
3. Results and Discussion 
3.1 Drug Excipient Compatibility Studies  
As per figure 1, IR spectrum of cefixime shows N-H stretch, C-H 
stretch, C=O stretch, COOH stretch, CH=CH stretch at 3429.2 cm-1, 
3139.90 cm-1, 1770.53 cm-1, 1382.87 cm-1 respectively and indicates the 
purity of cefixime (Fig. 1). 
There is no significant difference in characteristic peaks of pure drug and 
drug excipients mixture suggesting the absence of drug. The formulation 
contains Cefixime, xanthan gum, Eudragit RS100, Eudragit RL100 (Fig. 2). 
 
Fig. (1). FTIR study of Cefixime 
 
Fig. (2). Drug Excipient Interaction Study 
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3.2 Evaluation of Factorial Batch of Pellets 
3.1. Flow property of Pellets 
Pellets of proposed formulations were evaluated for Angle of 
repose, Loose Bulk density (LBD), Tapped bulk density (TBD), Hausner’s 
ration (HR) and Carr’s index (CI) (Table 5). Angle of repose of the all 
formulations was found to be in the range of 18.40 to 20.12 indicating 
acceptable range because of spherical shape of pellets and small size of 
pellets. The results of LBD and TBD for all formulations varied in the 
range of 0.60 g/cm3 to 0.67 g/cm3 and 0.67 g/cm3 to 0.75 g/cm3 
respectively. The CI ranged from 9.80 % to 13.69 % and HR was found to 
be in the range of 1.10 to 1.15 indicating that all formulations showed 
excellent flow properties and compressibility. 
 
Table 5: Evaluation of flow property of factorial batch of pellets 
 
Batch 
Code 
Bulk density 
(g/cm3) 
Tapped density 
(g/cm3) 
Hausner’s Ratio Carr’s 
Index 
Angle of Repose 
F1 0.63 0.73 1.15 13.69 18.50 
F2 0.65 0.74 1.13 12.16 19.69 
F3 0.66 0.75 1.13 12.00 18.88 
F4 0.61 0.69 1.13 11.59 19.13 
F5 0.64 0.71 1.10 9.80 20.12 
F6 0.67 0.75 1.11 10.66 18.15 
F7 0.60 0.67 1.11 10.44 19.75 
F8 0.62 0.69 1.15 10.14 19.29 
F9 0.63 0.71 1.12 11.26 18.40 
 
3.2 Evaluation of Pellets 
Pellets were evaluated for several of evaluation parameters and 
they were evaluated for % friability, mean particle size, % yield and % 
drug loading. The result of all factorial batches (F1-F9) was shown in table 
6 and that was found to be in good acceptable range. 
 
Table 6: Evaluation of Factorial Batch of Pellets 
 
Batch 
Code 
% Friability 
(n=3) 
Mean Particle Size (µm) (n=3) % Yield of     Pellets % Drug Loading 
F1 0.64 ±0.14 945 ±0.46 84 87 
F2 0.63 ±0.12 939 ±0.24 82 85 
F3 0.61 ±0.15 935 ±0.53 86 88 
F4 0.592 ±0.11 921 ±0.54 81 86 
F5 0.596 ±0.14 913 ±0.51 83 91 
F6 0.601 ±0.18 894 ±0.25 79 83 
F7 0.551 ±0.11 876 ±0.47 82 90.35 
F8 0.562 ±0.10 866 ±0.39 78.7 87 
F9 0.592 ±0.12 853 ±0.26 82.1 89.26 
 
% friability: All batches having the % friability in acceptable range. 
Friability is an important parameter for pellets which shows the 
fractureness of pellets and which generally occurring during 
transportation. All formulations % friability showed in range to <1. Thus, 
it was in acceptable range. 
Mean Particle size:  Particle size was determined by sieve shaker 
analysis. Particle size play very important role in drug release property 
and mainly the spheronization speed affect the value of particle size. As 
Spheronization speed increase, decrease in particle size which depicted 
in table 6. In above 9 factorial batches, at low speed of 500 rpm, particle 
size was found to be in range from 935 to 945µm for F1-F3 batches. At 
700 rpm, mean particle size of F4-F6 batches were in range from 894-
921 µm. At 900 rpm, F9 batch which having mean particle size 853µm 
due to higher speed of spheronizer. It was the smallest particle from all 
factorial batches. % drug loading: % Drug loading was carried out for 
F1-F9 batches and it was important to pellets. For all factorial batches, 
%drug loading was in range to 83-91%. % practical yield: % yield of 
pellets was calculated for all factorial batches and that was found to be in 
range from 78-86%. Low pellets yield occurred due to loss of material 
from extruder and spheronizer, during drying of t of pellets and also due 
to high rotational speed and dust formation occurred. 
3.3 In-vitro drug release studies of pellets 
In-vitro dissolution study for 9 batches was carried out and that 
was mentioned in Fig. 3. F1, F2, F3 batches gave drug release 95.20%, 
91.21%, 86.51% in 12 hours. Result showed that increase in Eudragit 
RS100 concentration, the drug release was retarded and it’s gave drug 
release for long time due to these batches having large particle size. F4, F5 
and F6 batches have particle size in medium range and smaller than F1-F3 
batches, that having drug release in 97.85%, 93.15% and 91.35% 
respectively. Factorial batches F7-F9 gave drug release as 95.86%, 
97.34% and 98.76% respectively. That showed that in 3 batches, 
concentration of Eudragit RS100 was increased and that decrease drug 
release and also particle size of these batches were small so drug release 
occurred in within 12hrs. Batch F9 showed drug release 98.76% in 12 hrs 
was good compared to all batches. This batch was optimizing batch and 
from this batch tablet was formulated. 
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Fig. (3). Cumulative percentage release of Cefixime Pellets F1-F9. 
3.4 Statistical Analysis of Factorial Batches 
All batches contained pellets which contains drug and polymer 
-copolymer in a different ratio. In 32 full factorial design here takes 
independent variable X1 (polymer copolymer ratio) and X2 
(spheronization speed). A 32 full factorial design was designed to study 
the effects of the polymer and copolymer and spheronization speed of 
extrusion spheronization on the Q6, t50, t90, diffusion exponent (n) and 
release rate constant (k) of pellets. The result of analysis of variance test 
for all three effects indicated that the test is significant (Table 7). 
 
Table 7:  Result of dependent variables 
 
Batch 
Code 
Variable Levels t50 t90 Q6 Diffusion Exponent (n) Release rate Constant (k) 
X1 X2 
F1 -1 -1 4.02 11.16 61.09 0.435 0.2946 
F2 0 -1 4.53 11.83 58.01 0.452 0.2713 
F3 1 -1 5.01 12.37 55.37 0.4753 0.2483 
F4 -1 0 2.82 9.58 68.78 0.4046 0.3470 
F5 0 0 3.53 11.08 63.04 0.4112 0.3172 
F6 1 0 4.21 11.69 59.54 0.4286 0.2903 
F7 -1 1 3.06 8.35 72.19 0.4618 0.3191 
F8 0 1 3.47 9.07 68.01 0.4815 0.2946 
F9 1 1 3.99 10.27 62.77 0.5067 0.2657 
A statistical model incorporating interactive and poly nominal terms used to evaluate the response (Equation 7). 
 
Y =b0 + b1X1 + b2X2+ b11X1X1 + b22X2X2+ b12X1X2      ……………………    (7) 
Where, Y is the dependent variable, b0 is the arithmetic mean 
response of 9 runs, and b1 is the estimated coefficients for the factor 
X1.The main effect (X1 and X2) represents the average result of changing 
one factor at a time from its low to high value. The interaction term 
(X1X2) shows how the responses changes when two factors are change 
simultaneously. The polynomial terms (X1X1, X2X2) are included to 
investigate nonlinearity.  
Analysis of variance (ANOVA) was performed to identify insignificant 
factors. Data were analysed using Microsoft Excel software. The reduced 
models were developed for response variables by removing the 
insignificant terms with P more than 0.05. The terms with P less than 
0.05 were considered statistically significance and retained in the 
reduced model. 
1. Full and reduced model of t50 (hr) 
Y =3.51 + 0.55X1 - 0.506X2 + 0.0083X1X1 + 0.4933X2X2 - 0.015X1X2 
…………….    (8) 
The coefficient of X1 that is, b1 bear positive sign and 
coefficient of X2 that is (Equation 8), b2 bear negative sign, and thus X1 
on increasing the polymer: copolymer ratio increasing t50 (time in hours 
required for the release of 50% of the cefixime). X2 is different 
Spheronization speed that effect the t50 was highest from 500RPM 
containing formulation, intermediate from 700 RPM containing 
formulation and lowest from 900 containing formulation. 
Table 8: Summary of results of regression analysis for t50 (hr) 
Response t50 (hr) b0 b1 b2 b11 b22 b12 R2 P 
FM 3.51 0.55 -0.506 0.0083 0.4933 -0.015 0.983 0.0006 
P Value 6.5E-05 0.0026 0.0034 0.940 0.017 0.850 - - 
RM 3.84 0.551 -0.50 - 0.0083 - 0.859 0.014 
 
Table 9: Calculation for testing the models in proportions for t50 (hr) 
 DF SS MS F  
 
Fcal = 0.024 
Fcri = 9.55 
Df = (2,3) 
Regression 
FM 5 3.854 0.770 36.23 
RM 3 3.366 1.122 10.174 
Residual 
FM 3 0.0638 0.02127  
RM 5 0.551 0.116  
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The significance level of coefficients b11 and b12 was found to 
be greater than P=0.05, thus they were omitted from the full model to 
generate the reduced model. The results of statistical analysis are shown 
in Table 8. The coefficients b1, b2 and b22 were found to be significant at P 
<0.05, thus they were retained in the reduced model. The reduced model 
was tested in portions to determine whether the coefficients b1, b2 and 
b22 contribute significant information for the prediction of t50. The results 
of testing the model in portions are shown in Table 9. The critical value of 
F for α = 0.05 is equal to (DF=2, 3). Since the calculated value (F=0.024) is 
less than the critical value (F=9.55), it may be concluded that the omitted 
term do not contribute significantly to the prediction of diffusion 
exponent (n). The results are shown in the form of response surface plot 
in fig. 4. 
 
Fig. (4). Response surface plot of t50 
Here positive sign of the X1 variable (polymer: copolymer 
ratio) indicate that increase the polymer to copolymer ratio here increase 
the time of the percentage drug release. It may be due to increase 
polymer copolymer ratio so particle sizes in a shape are increase that 
means drug release time are increase. 
Negative sign of X2 variable (spheronization speed) indicate 
that the here increase the spheronization speed decrease the time of the 
drug release due to concept here come that increase the spheronization 
speed there are decrease the particle size, decrease the particle size that 
means rapidly particle are dissolved or swallowed that means rapidly 
drug are released. 
2. Full and reduced model of t90 (hr) 
Y =10.84 + 0.8733X1 - 1.27X2 - 0.09X1X1 - 0.275X2X2 + 0.177X1X2 
……………  (9) 
The coefficient of X1 that is, b1 bear positive sign and 
coefficient of X2 that is, b2 bear negative sign, and thus X1 on increasing 
the polymer: copolymer ratio increasing diffusion exponent (Equation 9). 
X2 is different spheronization speed that effect the diffusion exponent 
was highest from 500 RPM containing formulation, intermediate from 
700 RPM containing formulation and lowest from 900 RPM containing 
formulation. 
The significance level of coefficients b11, b22 and b12 was found to be 
greater than P=0.05, thus they were omitted from the full model to 
generate the reduced model. The results of statistical analysis are shown 
in Table 10. The coefficients b1 and b2 were found to be significant at P 
<0.05, thus they were retained in the reduced model. The reduced model 
was tested in portions to determine whether the coefficients b1 and b22 
contribute significant information for the prediction of diffusion 
exponent (n). The results of testing the model in portions are shown in 
Table 11. The critical value of F for α = 0.05 is equal to (DF=3, 3). Since 
the calculated value (F=1.14) is less than the critical value (F=9.27), it 
may be concluded that the omitted term do not contribute significantly to 
the prediction of t90. The results are shown in the form of response 
surface plot in fig. 5. 
Table 10: Summary of results of regression analysis for t90 (hr) 
Response t90 (Hour) b0 b1 b2 b11 b22 b12 R2 P 
FM 10.84 0.8733 -1.27 -0.09 -0.275 0.177 0.982 0.0075 
P Value 1.78E-05 0.0052 0.0017 0.692 0.2752 0.3112 - - 
RM 10.6 0.873 -1.278 - - - 0.963 4.9E-05 
 
Table 11: Calculation for testing the models in proportions for t90 
(hr) 
 DF SS MS F  
Fcal=1.146 
Fcri=9.276 
Df=(3,3) 
Regression 
FM 5 14.674 2.934 2.93 
RM 2 14.38 7.190 78.511 
Residual 
FM 3 0.2560 0.0853  
RM 6 0.549 0.0915  
 
 
Fig. (5). Response surface plot of t90 
 
Here positive sign of the X1 variable (polymer: copolymer 
ratio) indicate that increase the polymer to copolymer ratio here increase 
the time of the percentage drug release. It may be due to increase 
polymer copolymer ratio so particle sizes in a shape are increase that 
means drug release time are increase. 
Negative sign of X2 variable (spheronization speed) indicate 
that the here increase the spheronization speed decrease the time of the 
drug release due to concept here come that increase the spheronization 
speed there are decrease the particle size, decrease the particle size that 
means rapidly particle are dissolved or swallowed that means rapidly 
drug are released. 
3. Full and reduced model of Q6 (%) 
Y =63.60 - 4.06X1 + 4.75X2 + 0.27X1X1 - 0.88X2X2 - 0.925X1X2 
………………  (10) 
The coefficient of X1 that is, b1 negative sign and coefficient of 
X2 that is, b2 bear positive sign, and thus X1 on increasing the polymer: 
copolymer ratio decrease the Q6 (Equation 10). X2 is different 
spheronization speed that effect the diffusion exponent was highest from 
500RPM containing formulation, intermediate from 700rpm containing 
formulation and lowest from 900 containing formulation. 
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Table 12: Summary of results of regression analysis for Q6 (%) 
Response Q6 (%) b0 b1 b2 b11 b22 b12 R2 P 
FM 63.60 -4.06 4.75 0.27 -0.88 -0.925 0.992 0.0022 
P Value 1.7E-06 0.0010 0.0006 0.6592 0.210 0.099   
RM 63.2 -4.06 4.75 - - - 0.971 2.3E-05 
 
Table 13: Calculation for testing the models in proportions for Q6 
(%) 
 DF SS MS F  
 
Fcal=2.78 
Fcri=9.27 
Df=(3,3) 
Regression 
FM 5 239.55 47.91 78.13 
RM 2 234.43 117.21 101.09 
Residual 
FM 3 1.8396 0.6132 - 
RM 6 6.95 1.159 - 
 
The significance level of coefficients b11, b22 and b12 was found 
to be greater than P=0.05, thus they were omitted from the full model to 
generate the reduced model. The results of statistical analysis are shown 
in table 12. The coefficients b1 and b2 were found to be significant at P 
<0.05, thus they were retained in the reduced model. The reduced model 
was tested in portions to determine whether the coefficients b1 and b22 
contribute significant information for the prediction of diffusion 
exponent (n). The results of testing the model in portions are shown in 
Table 13. The critical value of F for α = 0.05 is equal to (DF=3, 3). Since 
the calculated value (F=2.78) is less than the critical value (F=9.27), it 
may be concluded that the omitted term do not contribute significantly to 
the prediction of Q6 (%). The results are shown in the form of response 
surface plot in Fig. 6. 
 
Fig. (6). Response surface plot of Q6 (%) 
4. Full and reduced model of diffusion exponent (n) 
Y =0.4122 + 0.0182X1 + 0.014X2+ 0.0037X1X1 + 0.0539X2X2+ 
0.0011X1X2 …………. (11) 
The coefficient of X1 that is, b1 bear positive sign and 
coefficient of X2 that is, b2 bear positive sign, and thus X1 on increasing 
the polymer: copolymer ratio increasing diffusion exponent (Equation 
11). X2 is different spheronization speed that effect the diffusion 
exponent was highest from 500rpm containing formulation, intermediate 
from 700rpm containing formulation and lowest from 900rpm 
containing formulation. 
 
Table 14: Summary of results of regression analysis for diffusion exponent (n) 
Response diffusion exponent (n) b0 b1 b2 b11 b22 b12 R2 P 
FM 0.4122 0.0182 0.014 0.0037 0.0539 0.0011 0.987 0.0048 
P Value 3.21E-06 0.0057 0.010 0.458 0.0011 0.7382 - - 
RM 0.414 0.0182 0.014 0.053 - - 0.983 7E-05 
 
Table 15: Calculation for testing the models in proportions for 
diffusion exponent (n) 
 DF SS MS F  
 
Fcal=0.427 
Fcri=9.552 
Df=(2,3) 
Regression 
FM 5 0.0091 0.0018 46.341 
RM 3 0.0090 0.0030 99.79 
Residual 
FM 3 0.00011 3.93E-05 - 
RM 5 0.00015 3.03E-05 - 
 
The significance level of coefficients b11 and b12 was found to 
be greater than P=0.05, thus they were omitted from the full model to 
generate the reduced model. The results of statistical analysis are shown 
in Table 14. The coefficients b1, b2 and b22 were found to be significant at 
P <0.05, thus they were retained in the reduced model. The reduced 
model was tested in portions to determine whether the coefficients b1, b2 
and b22 contribute significant information for the prediction of diffusion 
exponent (n). The results of testing the model in portions are shown in 
Table 15. The critical value of F for α = 0.05 is equal to (DF=2, 3). Since 
the calculated value (F=0.427) is less than the critical value (F=9.55), it 
may be concluded that the omitted term do not contribute significantly to 
the prediction of diffusion exponent (n). The results are shown in the 
form of response surface plot in Fig. 7. 
 
Fig. (7). Response surface plot of diffusion exponent (n) 
 
5. Full and reduced model for release rate constant (k) 
Y = 0.3183 - 0.026X1 + 0.010X2 - 0.0002X1X1 - 0.035X2X2 - 0.00178X1X2 
…………….  (12) 
The coefficient of X1 that is, b1 bear negative sign and 
coefficient of X2 that is, b2 bear positive sign, and thus X1 on increasing 
the polymer: copolymer ratio increasing diffusion exponent (Equation 
12). X2 is different spheronization speed that effect the diffusion 
exponent was highest from 500RPM containing formulation, 
intermediate from 700 RPM containing formulation and lowest from 
900RPM containing formulation. 
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Table 16: Summary of results of regression analysis for release rate constant (k) 
Response release rate constant (k) b0 b1 b2 b11 b22 b12 R2 P 
FM 0.3183 -0.026 0.010 -0.0002 -0.035 -0.00178 0.99 0.0004 
P Value 4.9E-07 0.00014 0.001 0.920 0.0002 0.264   
RM 0.3181 -0.026 0.010 -0.035 - - 0.99 2.68E-06 
 
Table 17: Calculation for testing the models in proportions for 
release rate constant (k) 
 DF SS MS F  
 
Fcal=0.941 
Fcri=9.55 
Df=(2,3) 
Regression 
FM 5 0.007376 0.0014 219.03 
RM 3 0.0073 0.0024 373.14 
Residual 
FM 3 2.02E-05 6.73E-06 - 
RM 5 3.29E-05 6.58E-06 - 
 
The significance level of coefficients b11 and b12 was found to 
be greater than P=0.05, thus they were omitted from the full model to 
generate the reduced model. The results of statistical analysis are shown 
in Table 16. The coefficients b1, b2 and b22 were found to be significant at 
P <0.05, thus they were retained in the reduced model. The reduced 
model was tested in portions to determine whether the coefficients b1, b2 
and b22 contribute significant information for the prediction of diffusion 
exponent (n). The results of testing the model in portions are shown in 
Table 17. The critical value of F for α = 0.05 is equal to (DF=2, 3). Since 
the calculated value (F=0.941) is less than the critical value (F=9.55), it 
may be concluded that the omitted term do not contribute significantly to 
the prediction of diffusion exponent (n). The results are shown in the 
form of response surface plot in fig. 8. 
 
Fig. (8). Response surface plot of release rate constant (k) 
 
Kinetic Modeling of Dissolution Data  
The kinetics of the dissolution data were well fitted to zero 
order, Higuchi model and Krosemeyer-Peppas model as evident from 
regression coefficients (table 20). The value of diffusion exponent (n) for 
F1 to F9 factorial formulations was between 0.4046 to 0.5061 so it 
indicates Fickian diffusion of the drug from formulation which 
corresponds to diffusion, erosion and swelling mechanism. Kinetic model 
Higuchi indicating that R2 value of F1 to F9 was between 0.981 to 0.998 
shows that drug release type was diffusion type from gel network and 
extended drug release for longer period of time. Kinetic Model Zero order 
indicating that R2 value of F1 to F9 was in range 0.981 to 0.999 that near 
about 1.000 clearly mentioned that drug release from stiff gel networking 
was Zero order drug release that not depend on concentration of drug. 
 
Table 18: Kinetic Modeling of Dissolution Data 
 
Formulation Code F1 F2 F3 F4 F5 F6 F7 F8 F9 
Zero order 
S 5.59 5.481 5.42 5.912 5.297 5.346 7.564 7.139 6.374 
I 27.54 25.13 22.86 33.31 31.26 27.45 26.81 25.18 24.53 
R2 0.999 0.998 0.998 0.999 0.997 0.998 0.999 0.999 0.994 
First order 
S 0.040 0.041 0.043 0.039 0.037 0.039 0.0533 0.051 0.046 
I 1.523 1.489 1.455 1.583 1.555 1.5164 1.522 1.504 1.491 
R2 0.991 0.989 0.987 0.986 0.982 0.989 0.993 0.996 0.976 
Higuchi 
S 25.45 24.98 24.78 26.11 24.34 24.37 30.49 30.09 29.28 
I 1.85 -0.12 -2.33 7.57 6.35 2.79 -0.769 -3.17 -5.400 
R2 0.984 0.985 0.987 0.991 0.992 0.986 0.985 0.985 0.988 
Hixon Crowell 
S -1.864 -1.827 -1.809 -1.970 -1.765 -1782 -2.52 -2.379 -2.124 
I 24.15 24.95 25.73 22.22 22.91 24.18 24.39 24.93 25.154 
R2 -0.999 -0.998 -0.998 -0.999 -0.997 -0.998 -0.999 -0.999 -0.994 
Korsemeyer and Peppas 
N 0.4350 0.4520 0.4753 0.4046 0.4112 0.4286 0.4618 0.4815 0.5061 
I -0.530 -0.566 -0.604 -0.459 -0.4986 -0.5370 -0.496 -0.530 -0.575 
R2 0.978 0.976 0.980 0.986 0.984 0.977 0.980 0.981 0.978 
S= Slope, I= Intercept, R2= Square of correlation coefficient, n = Diffusion exponent 
 
Kinetic Model First order indicating that R2 value of F1 to F9 
was between 0.956 to 0.986 that having less than Zero order release R2 
value (Table 18), mentioned that drug release type was not first order 
release from gel network. 
Comparison of Dissolution Profiles for Selection of Optimum Batch 
The values of Dissimilarity factor (f1) for batches F1, F2, F3, F4, 
F5, F6, F8, and F9 were less than 15 compared with theoretical 
dissolution profile indicating good similarity in dissolution. The batch F9 
showed minimum value of f1 (3.09). The values of similarity factor (f2) for 
batches F1, F2, F3, F4, F5, F6, F8, and F9 were greater than 50 compared 
with theoretical dissolution profile indicating good similarity in 
dissolution. The batch F9 showed maximum value of f2 (77.90) and result 
are depicted in Table 19. 
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Table 19: Similarity Factor (f2) and Dissimilarity factor (f1) for F1-F9 
Batch F1 F2 F3 F4 F5 F6 F7 F8 F9 
Similarity factor (f2) 75.68 64.61 56.82 57.25 69.46 67.41 51.16 60.23 77.90 
Dissimilarity factor (f1) 4.14 6.73 10.33 11.68 5.85 5.80 17.11 10.36 3.09 
Check Point Batch  
The 32 factorial designs were run with one check point 
composition of which is shown in Table 20. Batch CP1 was prepared to 
validate the derived equation for in-vitro dissolution time of pellets with 
one check point composition. The data for in vitro dissolution time for the 
predicted and observed values are shown in table 20.   
 
Table 20: Composition and Evaluation parameter and in-vitro dissolution of check point batch 
Check point batch (CP1) 
In-vitro dissolution study 
t50 t90              Q6 
P O P O P O 
X1= -0.5; X2= +0.5; X3= 7.5 2.86 3.84 9.63 9.98    68.0   64.0 
Check point batch (CP1) 
In-vitro dissolution study 
Exponential constant (n) Release rate constant (k). 
P O P O 
X1=  -0.5; X2 = +0.5; X3= 7.5 0.4234 0.4718 0.3279 0.2858 
*P= Predicted value; O = Observed value 
It can be observed that the predicted value and observed value 
for CP1 for in-vitro dissolution time of pellets were nearly similar with 32 
factorial designs batches. It can be concluded that the evolved model can 
be used for prediction of response i.e. in-vitro dissolution time of pellets 
within the simplex space. Comparative analysis of the predicted value 
and experimental value using paired t – test indicated that there was no 
significant difference between the two values thereby establishing 
validity of generated mode. In this research work between the tstat (0.60) 
and tcri (2.77) not significant difference and tcri value very high as 
compare to tstat. 
In the present research work, no very much difference 
between factorial batches and one check point composition small 
between predicted and experimental value. 
5.8 Evaluation of Fast Disintegrating Tablets 
The physical parameters such as hardness, weight variation 
test, % friability, % drug content, wetting time and disintegration time of 
all the formulated tablets were given in Table 21. Hardness of all the 
tablets (F1-F9) was in the range of 3.4±0.12 kg/cm2 to 3.7±0.12 kg/cm2. 
The percentage friability ranged from 0.81±0.17 % to 0.91±0.13 % i.e. 
less than 1% and all batches comply this test. According to IP, ±5% 
weight variation is acceptable range for this test and average percent 
deviation of all the tablets (F1-F9) were found within the limit hence all 
formulation passed the weight variation test. The % drug content was 
found to be uniform and ranged from 95.82±0.11 % to 99.78±0.10 %. The 
wetting time ranged from 30±3 to 53±3. Batch F9 having wetting time 30 
sec. so, from result it showed that increase in concentration of super- 
disintegrants resulted in decrease in wetting time. The disintegration 
time ranged from 42±2 to 71±2. From the result it was found that 
increasing of concentration of super disintegrants that resulted in 
decreasing the disintegration time. Batch F7 and F9 having disintegration 
in 42 sec. 
 
Table 21: Evaluation of Fast Disintegrating Tablets 
Batch 
Code 
Hardness 
(Kg/cm2)* 
Weight Variation 
(mg) (n=20) 
Friability 
(%)* 
Drug Content 
(%)* 
Wetting Time (Sec)* Disintegration 
Time (sec)* 
F1 3.5±0.10 1469.5 ±1.25 0.85 ±0.13 98.27 ±0.11 52 ±2 70 ±3 
F2 3.4 ±0.12 1445.5 ±1.37 0.83 ±0.15 96.22 ±0.16 49 ±3 69 ±2 
F3 3.6 ±0.14 1511.6 ±1.25 0.81 ±0.17 99.48 ±0.12 53 ±3 71 ±2 
F4 3.5 ±0.19 1485.4 ±1.52 0.89 ±0.14 101.1 ±0.10 41 ±2 63 ±3 
F5 3.4 ±0.17 1536.7 ±1.65 0.90 ±0.16 97.42 ±0.13 40 ±4 62 ±2 
F6 3.5 ±0.20 1454.9 ±1.45 0.82 ±0.11 95.82 ±0.11 40 ±2 63 ±2 
F7 3.7 ±0.12 1528.3 ±1.26 0.83 ±0.14 103.2 ±0.16 31 ±3 42 ±3 
F8 3.5 ±0.22 1533.9 ±1.53 0.91 ±0.13 99.78 ±0.10 32 ±2 43 ±1 
F9 3.6 ±0.20 1494.6 ±1.56 0.81 ±0.17 98.64 ±0.14 30 ±3 42 ±2 
*= mean SD (n=3) 
 
In-vitro dissolution study of Fast Disintegrating Tablet 
In- vitro dissolution study for 9 formulation batches was 
carried out and that was mentioned in fig. 9. F1, F2, F3 batches gave drug 
release 94.43%, 90.82%, 84.97% in 12 hours. Result showed that increase 
in polymer concentration, the drug release was retarded and it’s gave 
drug release for long time. Also these batches having large particle size. 
F4, F5 and F6 batches have particle size in medium range and smaller 
than F1-F3 batches, that having drug release in 96.43%, 92.54% and 
92.15% respectively. Factorial batches F7-F9 gave drug release as 
93.56%, 96.86% and 97.79% respectively. That showed that in 3 batches, 
concentration of Eudragit RS100 was increased and that decrease drug 
release and also particle size of these batches were small so drug release 
occurred in within 12hrs. Batch F9 showed drug release 97.79% in 12 hrs 
was good compared to all batches. This batch was optimizing batch and 
from this batch tablet was formulated. 
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Fig. (9). In-vitro Drug release studies of fast disintegrating tablets of F1 to F9 
 
Evaluation of Reconstitutable SR Suspension 
Organoleptic Property of Reconstitutable Suspension 
Organoleptic property of SR Suspension was evaluated and it 
was found that all F1-F9 batches having red color and odour was cherry. 
That showed in table 27. 
Viscosity 
Viscosity of suspension was measured by Brook-Field 
viscometer. Viscosity of all formulation was shown in Table 22. Xanthan 
gum having used in several of concentration and that the result showed 
batches F3, F6 and F9 had high viscosity than other batches. High 
viscosity of suspension results in high sedimentation volume and better 
Redispersibility. As the viscosity of suspension was high, the solid 
materials sediment slowly and also prevents sedimentation of solid 
material. So the number of strokes was less required and by this 
redispersibility was good. 
Redispersibility 
Redispersibility was important factor if there is no 
redispersion then it will lead to caking of solid content and if caking 
occurs then that results in non-uniform dose of drug. Because drug will 
remain in cake, it was measured by means of number of strokes required. 
Minimum number of strokes required for batches F3 and F9 was 7.  
 
 
 
 
Table 22: Evaluation of Reconstitutable SR Suspension 
Batch 
Code 
pH Viscosity 
(cps) 
Redispersibility 
(No. of strokes) 
Color Odour 
F1 6.9 688 11 Red Cherry 
F2 6.8 710 9 Red Cherry 
F3 6.9 735 7 Red Cherry 
F4 6.6 686 10 Red Cherry 
F5 6.7 713 9 Red Cherry 
F6 6.8 734 8 Red Cherry 
F7 6.6 690 11 Red Cherry 
F8 6.8 708 8 Red Cherry 
F9 6.5 737 7 Red Cherry 
Sedimentation Volume 
The sedimentation volume was measured to check the physical 
stability of the suspension. The sedimentation volume has values ranging 
from less than 1 that was shown in Table 23. The sedimentation volume 
(F) should be at least 0.9 for 1 hr but a longer period is preferred for our 
purpose. The sedimentation volume in above formulations is shown in 
Table 23. The results showed that for formulation batch F3, F6 and F9 
the sedimentation volume was 0.914, 0.9 and 0.914 respectively even 
after 7 days which is nearer to the standard value of sedimentation 
volume 1. Means no sediment of the solid content occurred at the end of 
7 days. So the formulation of batch F3, F6 and F9 was better than all 
other formulation as they all had sedimentation volume less than batch 
F3, F6 and F9. 
Table 23: Evaluation of Sedimentation volume of Reconstitutable SR Suspension 
 
 
Formulations 
Height of Sediment (cm) After Sedimentation 
Volume 
F=Hu/Ho 
3 
Min 
Ho 
1 
Day 
2 
Day 
3 
Day 
4 
Day 
5 
Day 
6 
Day 
7 
Day 
Hu 
F1 7.0 6.2 5.3 4.4 4.3 3.4 3.2 3.2 0.457 
F2 7.0 6.4 5.2 5.0 4.8 4.7 4.4 4.3 0.614 
F3 7.0 6.7 6.6 6.5 6.5 6.4 6.4 6.4 0.914 
F4 7.0 6.2 5.2 4.3 4.2 3.3 3.1 3.1 0.442 
F5 7.0 6.5 5.5 4.9 4.7 4.7 4.3 4.2 0.600 
F6 7.0 6.6 6.5 6.5 6.4 6.4 6.3 6.3 0.900 
F7 7.0 6.4 5.3 4.2 4.1 3.3 3.1 3.0 0.428 
F8 7.0 6.6 5.6 5.2 4.9 4.8 4.6 4.5 0.640 
F9 7.0 6.8 6.6 6.5 6.5 6.4 6.4 6.4 0.914 
 
Accelerated Stability Study of Reconstitutable SR Suspension 
The optimize formulation was evaluated to carry out 
accelerated stability study for 18 days and the physical property of 
suspension with sedimentation volume, Redispersibility, pH and % drug 
release was evaluated.  The data depicted in table 24. After 18 days, no 
change in odour and colour of suspension. The pH was found to be 6.3 
and sedimentation volume was 6.1, redispersibility was found to be no. of 
strokes was required 8. The dissolution data was found that after 18 days 
96.58% drug release occurred in 12 hours. 
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Table 24: Evaluation of Accelerated Stability study of 
Reconstitutable SR Suspension 
Evaluation Parameters Initial After 18 days 
Colour Red Red 
Odour Cherry Cherry 
pH 6.5 6.3 
Sedimentation volume 6.4 6.1 
Redispersibility 7 8 
% Drug Release 97.79 96.58 
 
Comparison of suspension with Marketed suspension (ZIFI 100) 
Cefixime reconstitutable suspension was compared with 
marketed product of cefixime suspension and was evaluated for physical 
property, pH, sedimentation volume, redispersibility, % drug release. The 
result was showed in Table 26. 
 
 
 
Table 25: In-Vitro Dissolution Study of Marketed Suspension (ZIFI 100) 
Time (min) 0 5 10 20 30 40 50 
CPR 0 17.29 36.18 53.47 69.13 82.56 97.12 
Standard deviation value of final batch is within limits (±1.5) 
Average of three dissolution data  (n=3) 
 
 
Fig. (10). In-vitro drug release studies of Marketed Cefixime Suspension 
Marketed suspension required no. of strokes was 9 compared 
to reference suspension and sedimentation volume of marketed 
suspension was 6.1 in compared to reference. Viscosity of reference 
suspension was less compared to marketed suspension. The dissolution 
data was showed that marketed cefixime suspension had % drug release 
97.12% in 50min (Fig. 10) and reference suspension had drug release 
97.79% in 12hrs. The result was showed in Table 25. So reference 
suspension had good property and sustained release property compared 
to marketed suspension so it was better and will be widely applicable in 
industry. 
Table 26: Comparison of suspension with marketed suspension 
Evaluation Parameters Cefixime Suspension (Reference) Cefixime Suspension 
(Marketed Product ‘ZIFI100’) 
Colour Red Orange 
Viscosity (cps)  737 791 
pH 6.5 6.7 
Sedimentation Volume 6.4 6.1 
Redispersibility 7.0 9.0 
% Drug Release 97.79 (in 12 hrs) 97.12 (in 50 min) 
 
4. Conclusion 
It was concluded that drug to polymer ratio and 
Spheronization speed had a significant effect on percentage yield, particle 
size, and drug release rate. It was found that pellets containing sodium 
alginate had low friability (due to higher matrix forming property) 
compared to pellets prepared from Eudragit RS100 and RL100 (poor 
matrix forming property). Drug release rate decreases with increase in 
the concentration of drug to polymer ratio in which single of polymer 
was unable to retard the drug release for 12 hrs. It was also concluded 
that particle size decreases with increase in spheronization speed. 
Optimized formulation (F9) showed 98.76% drug release at the end of 12 
hrs and maximum similarity factor (f2=77.90) and minimum dissimilarity 
factor (f1=3.09) with Theoretical release profile of Cefixime. 
Disintegration time decreases with increase in concentration of 
superdisintegrant and viscosity of suspension increases with increase in 
concentration of suspending agent that result in better redispersibility.  
Comparative analysis of the predicted value and experimental 
value using paired t – test indicated that there was no significant 
difference between the two values thereby establishing validity of 
generated mode of Evaluation parameter and in-vitro dissolution time of 
pellets with one check point composition. 
Various kinetic models confirmed that in-vitro release kinetic 
of optimized batch (F9) was best fitted to zero order model & Higuchi 
with anomalous non-fickian release mechanism. The optimized batch 
was found to be stable after 18 days at accelerated condition. 
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